Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.

por Thatcher, N., Dazzi, H., Johnson, R. J., Russell, S., Ghosh, A. K., Moore, M., Chadwick, G., Craig, R. D.
Publicado 1989